A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder

OBJECTIVE: To assess the efficacy of liraglutide 3.0 mg, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, for binge eating disorder (BED). METHODS: Adults with a body mass index (BMI) ≥ 27 kg/m(2) enrolled in a pilot, 17‐week double‐blind, randomized controlled trial of liraglutide 3.0 mg/day for...

Descripción completa

Detalles Bibliográficos
Autores principales: Allison, Kelly C., Chao, Ariana M., Bruzas, Maija B., McCuen‐Wurst, Courtney, Jones, Elizabeth, McAllister, Cooper, Gruber, Kathryn, Berkowitz, Robert I., Wadden, Thomas A., Tronieri, Jena S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073825/
https://www.ncbi.nlm.nih.gov/pubmed/37034559
http://dx.doi.org/10.1002/osp4.619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073825/
https://www.ncbi.nlm.nih.gov/pubmed/37034559
http://dx.doi.org/10.1002/osp4.619

Ejemplares similares